Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Rani Therapeutics Holdings (RANI) Profit After Tax (2020 - 2025)

Rani Therapeutics Holdings (RANI) has 6 years of Profit After Tax data on record, last reported at -$5.4 million in Q3 2025.

  • For Q3 2025, Profit After Tax rose 57.46% year-over-year to -$5.4 million; the TTM value through Sep 2025 reached -$18.5 million, up 77.37%, while the annual FY2024 figure was -$30.0 million, 55.78% up from the prior year.
  • Profit After Tax reached -$5.4 million in Q3 2025 per RANI's latest filing, up from -$11.2 million in the prior quarter.
  • Across five years, Profit After Tax topped out at $10.8 million in Q4 2024 and bottomed at -$41.5 million in Q4 2022.
  • Average Profit After Tax over 5 years is -$13.7 million, with a median of -$12.7 million recorded in 2025.
  • Peak YoY movement for Profit After Tax: plummeted 575.17% in 2021, then surged 208.41% in 2023.
  • A 5-year view of Profit After Tax shows it stood at -$38.9 million in 2021, then fell by 6.89% to -$41.5 million in 2022, then increased by 1.28% to -$41.0 million in 2023, then skyrocketed by 126.44% to $10.8 million in 2024, then tumbled by 149.91% to -$5.4 million in 2025.
  • Per Business Quant database, its latest 3 readings for Profit After Tax were -$5.4 million in Q3 2025, -$11.2 million in Q2 2025, and -$12.7 million in Q1 2025.